1. Metformin attenuates white matter injury in neonatal mice through activating NRF2/HO-1/NF-κB pathway.
- Author
-
Xie W, Ding B, Lou J, Wang X, Guo X, and Zhu J
- Subjects
- Animals, Mice, Oxidative Stress drug effects, Disease Models, Animal, Male, Mice, Inbred C57BL, Humans, Membrane Proteins, Heme Oxygenase-1, NF-E2-Related Factor 2 metabolism, Metformin pharmacology, Metformin therapeutic use, Animals, Newborn, NF-kappa B metabolism, White Matter drug effects, White Matter metabolism, White Matter pathology, Signal Transduction drug effects, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use
- Abstract
White matter injury (WMI) is a major form of brain injury that occurs in preterm infants and develops into lifelong disabilities, including cerebral palsy, impaired cognitive function, and psychiatric disorders. Metformin (MET) has been reported to have neuroprotective effects. However, whether MET is responsible for neuroprotection against WMI remains unclear. In this study, we established a WMI model in neonatal mice to explore the neuroprotective effects of MET and attempted to elucidate its potential mechanisms. Our results showed that MET increased the expression of myelin basic protein (MBP), oligodendrocyte transcription factor 2 (Olig2), and CC1, improved the thickness and density of the myelin sheath, and reduced oxidative stress and microglial infiltration after chronic hypoxia induction. Moreover, MET improved memory, learning, and motor abilities as well as relieved anxiety-like behaviors in mice with WMI. These protective effects of MET may involve the upregulation of the nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1(HO-1)/NF-κB pathway related protein expressions. In addition, the NRF2 inhibitor ML385 could significantly reverse the effects of MET. In conclusion, this study suggested that MET attenuated chronic hypoxia-induced WMI through activating the NRF2/HO-1/NF-κB pathway, indicating that MET might be a promising therapeutic option for WMI., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF